This trial is designed to estimate the efficacy of a carfilzomib-based triplet in first or second relapse of multiple myeloma for subjects refractory to lenalidomide and exposed to daratumumab The study is an open-label, phase 2 trial. Approximately 85 subjects will be enrolled in the study. Subjects may receive treatment until progression.
SparkCures ID | 1065 |
---|---|
Trial Phase | Phase 2 |
Enrollment | 53 Patients |
Treatments |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria
Exclusion Criteria
Please visit the ClinicalTrials.gov page for historical site information.
View Centers